Metabolic reprogramming in cancer is not only a biological hallmark but also reveals
treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment …

Lipid metabolic reprogramming is an emerging hallmark of cancer. In order to sustain
uncontrolled proliferation and survive in unfavorable environments that lack oxygen and …

Angiogenesis is a hallmark of cancer and is required for tumor growth and progression.
Antiangiogenic therapy has been revolutionarily developing and was approved for the …

Abstract cGAS-STING pathway, as an essential intracellular immune response pathway, has
attracted much attention in tumor immunotherapy. However, low metabolic stability of …

Acquired resistance represents a bottleneck for effective molecular targeted therapy in lung
cancer. Metabolic adaptation is a distinct hallmark of human lung cancer that might …

The development of drug resistance remains a major challenge in cancer treatment.
Ferroptosis, a unique type of regulated cell death, plays a pivotal role in inhibiting tumour …

P-glycoprotein (P-gp) is a major factor in the multidrug resistance phenotype in cancer cells.
P-gp is a protein that regulates the ATP-dependent efflux of a wide range of anticancer …

Drug resistance remains a major hurdle to successful cancer treatment, being accountable
for approximately 90% of cancer-related deaths. In the past years, increasing attention has …

NSCLC is the leading cause of cancer mortality and represents a major challenge in cancer
therapy. Intrinsic and acquired anticancer drug resistance are promoted by hypoxia and HIF …

Simple Summary Drug therapy is an important treatment for cancer patients; however, drug
resistance severely affects the survival time and quality of life of cancer patients. Oxidative …